ISO 10993-7 plays a crucial role in ensuring the safety of medical devices sterilized using ethylene oxide (EO). This standard is part of the ISO 10993 series, which focuses on the biological evaluation of medical devices. It specifically establishes acceptable limits for residual EO and its byproducts, such as ethylene chlorohydrin (ECH) and ethylene glycol (EG), in order to mitigate potential health risks to patients.
This article provides an in-depth exploration of ISO 10993-7, including its objectives, permissible limits, methods of analysis, and the impact of the latest updates on medical device manufacturers.
In the context of the product life cycle, the evaluation of the biocompatibility of medical devices is of fundamental importance. We have already been extensively discussing about biocompatibility topics, such as, for example, hemocompatibility, ISO 10993-1, cytotoxicity, etc . In the last years, several changes have been implemented in ISO standards and having implemented a solid approach to evaluate all these new requirements became of vital importance.
Objective of ISO 10993-7
The main objective of ISO 10993-7 is to set safe limits for ethylene oxide residues in medical devices. EO is widely used in sterilization due to its efficacy against bacteria, viruses, and fungi. However, it leaves behind toxic residues, which, if not properly removed, can cause serious health issues, including:
- Irritation of the respiratory system and skin
- Organ damage
- Carcinogenic effects
- Negative reproductive effects
To mitigate these risks, ISO 10993-7 provides guidelines for determining and controlling residual levels in devices before they are released to the market.
Limits Based on Contact Duration
ISO 10993-7 categorizes medical devices into three exposure groups, based on how long they are expected to be in contact with the patient:
- Limited Exposure Devices (≤ 24 hours)
- Prolonged Exposure Devices (> 24 hours but ≤ 30 days)
- Permanent Contact Devices (> 30 days)
Each category has specific limits for EO and ECH residues to minimize patient exposure:
Permanent Contact Devices:
- EO: ≤ 0.1 mg/day (max 4 mg in the first 24 hours, 60 mg in the first 30 days, and 2.5 g over a lifetime)
- ECH: Not specifically addressed in general limits
- For babies and infants: Limits are adjusted for body weight (0.02 mg/kg/day for EO, 0.029 mg/kg/day for ECH)
Prolonged Exposure Devices:
- EO: ≤ 2.0 mg/day (max 4 mg in the first 24 hours, 60 mg in the first 30 days)
- For babies and infants: Adjusted based on weight (0.3 mg/kg/day for EO, 0.27 mg/kg/day for ECH)
Limited Exposure Devices:
- EO: ≤ 4 mg/day
- ECH: ≤ 9 mg/day
- For babies and infants: (0.3 mg/kg/day for EO, 0.64 mg/kg/day for ECH)
These limits consider body mass for pediatric patients, ensuring a more patient-specific approach compared to the previous “one-size-fits-all” method.
Analytical Methods for Compliance
ISO 10993-7 outlines two key residue extraction procedures before analysis:
Simulated-Use Extraction (Reference Method)
- Uses water extraction to measure the actual residue levels that could be released during device use.
- Typically used for Limited Exposure (A) and Prolonged Exposure (B) devices.
Exhaustive Extraction
- Extracts residues until the amount in a subsequent extraction is <10% of the first.
- Typically used for Permanent Contact (C) devices.
The gold standard for analysis is Headspace Gas Chromatography (GC), which allows precise quantification of EO and ECH residues.
Challenges in Compliance with ISO 10993-7
1. Residues Below Detection Limits
With the updated standard lowering permissible limits, especially for infants, some manufacturers face difficulties in accurate quantitation due to limitations in current analytical methods.
2. Sample Integrity and Storage
ISO 10993-7 emphasizes the importance of sample selection, handling, and storage to ensure accurate testing. Recommendations include:
- Selecting worst-case samples (e.g., those with the shortest aeration time)
- Using dry-ice transportation to prevent premature outgassing
- Storing samples at -20°C until analysis
3. Regulatory Impact on Manufacturers
Compliance with ISO 10993-7 is mandatory in many regulatory markets, including the EU (MDR 2017/745) and the US (FDA requirements). Failure to meet these requirements can lead to regulatory rejection and product recalls.
Best Practices for Compliance with ISO 10993-7
To ensure compliance with ISO 10993-7, manufacturers should:
✅ Optimize sterilization and aeration processes to minimize residual EO and ECH.
✅ Regularly validate analytical methods to ensure they can detect low residue levels.
✅ Select appropriate extraction procedures based on device category.
✅ Perform worst-case testing by considering factors like stacking in packaging and aeration conditions.
✅ Engage with experienced testing laboratories to ensure accurate compliance reporting.
Conclusions
ISO 10993-7 plays a critical role in protecting patient health by ensuring medical devices sterilized with EO meet stringent safety requirements. The recent differentiation of limits for babies and infants marks a significant improvement in patient-centric regulation.
Manufacturers must stay up to date with evolving regulatory requirements and implement robust compliance strategiesto avoid costly setbacks. By following best practices in residue testing, sample handling, and analytical validation, companies can ensure their products meet ISO 10993-7 and contribute to safer medical device manufacturing.
Are you looking for expert guidance on ISO 10993-7 compliance? Contact us today for specialized EO residue analysis and consulting services to ensure your medical devices meet the highest safety standards.
Subscribe to 4EasyReg Newsletter
4EasyReg is an online platform dedicated to Regulatory matters within the medical device, information security and AI-Based business.
We offer a wide range of documentation kits to support your compliance efforts towards a wide range of standards and regulations, such as ISO 13485, EU MDR, ISO 27001, ISO 42001 and much more. . Specifically, in our webshop you will find:
- ISO 13485 Documentation / Compliance Kit
- ISO 27001 Documentation / Compliance Kit
- ISO 42001 Documentation / Compliance Kit
- FDA Cybersecurity Documentation
Within our sister platform QualityMedDev Academy, a wide range of online & self-paced training courses is available, such as for example:
- Complaint Handling and Vigilance Reporting
- Artificial Intelligence in Medical Device. Regulatory Requirements
- Unique Device Identification (UDI) Requirements according to EU MDR
- Clinical Evaluation Process According to EU MDR
- Medical Device SW Verification & Validation
- Risk Management for Medical Devices
- Usability Evaluation for Medical Devices
As one of the leading online platforms in the medical device sector, 4EasyReg offers extensive support for regulatory compliance. Our services cover a wide range of topics, from EU MDR & IVDR to ISO 13485, encompassing risk management, biocompatibility, usability, software verification and validation, and assistance in preparing technical documentation for MDR compliance.
Do not hesitate to subscribe to our Newsletter!
